CASI Overview

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Wall Street analysts forecast CASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CASI Pharmaceuticals Inc revenue for the last quarter amounts to 3.08M USD, decreased -60.54

CASI Pharmaceuticals Inc. EPS for the last quarter amounts to -0.68 USD, increased 23.64

CASI Pharmaceuticals Inc (CASI) has 233 emplpoyees as of March 17 2026.

Today CASI has the market capitalization of 65.67M USD.